A Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
The primary purpose is to study the efficacy, safety, and tolerability of LY2216684 as an
adjunctive treatment for participants with major depressive disorder (MDD), who were
identified as partial responders to an adequate course of treatment with a selective
serotonin reuptake inhibitor (SSRI) (as defined by history).